Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2020 · 10-Q
Revenue$19.97M$19.97M−53.2% vs Q3 2019 Net Income-$58.23M-$58.23MN/M vs Q3 2019 EPS Diluted-$0.64-$0.64N/M vs Q3 2019 Gross Profit$12,795,000−49.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$42,054,000N/M Free Cash Flowderived-$42,686,000N/M Margins · derivedGross margin64.1%+4.4 pt vs Q3 2019
Operating margin-292.4%−210.7 pt vs Q3 2019
Net margin-291.7%−212.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 5, 2020 · 36 d after period end